278 related articles for article (PubMed ID: 28538291)
1. Subclinical Antibody-Mediated Rejection.
Arias M; Serón D; Herrero I; Rush DN; Wiebe C; Nickerson PW; Ussetti P; Rodrigo E; de Cos MA
Transplantation; 2017 Jun; 101(6S Suppl 1):S1-S18. PubMed ID: 28538291
[No Abstract] [Full Text] [Related]
2. The Importance of Bringing Transplantation Tolerance to the Clinic.
Cosimi AB; Ascher NL; Emond JC; Kaufman DB; Madsen JC; Miller J; Monaco AP; Montgomery RA; Newell KA; Sánchez-Fueyo A; Sarwal MM; Scandling JD; Strober S; Todo S; Weir MR; Sachs DH
Transplantation; 2021 May; 105(5):935-940. PubMed ID: 33901128
[No Abstract] [Full Text] [Related]
3. Factors Predicting Risk for Antibody-mediated Rejection and Graft Loss in Highly Human Leukocyte Antigen Sensitized Patients Transplanted After Desensitization.
Vo AA; Sinha A; Haas M; Choi J; Mirocha J; Kahwaji J; Peng A; Villicana R; Jordan SC
Transplantation; 2015 Jul; 99(7):1423-30. PubMed ID: 25606792
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of donor-specific human leukocyte antigen antibodies in liver transplantation.
Cuadrado A; San Segundo D; López-Hoyos M; Crespo J; Fábrega E
World J Gastroenterol; 2015 Oct; 21(39):11016-26. PubMed ID: 26494958
[TBL] [Abstract][Full Text] [Related]
5. Increasing relevance of donor-specific antibodies in antibody-mediated rejection.
Zito A; Schena A; Grandaliano G; Gesualdo L; Schena FP
J Nephrol; 2013; 26(2):237-42. PubMed ID: 23475460
[TBL] [Abstract][Full Text] [Related]
6. The Influence of Immunosuppressive Agents on the Risk of De Novo Donor-Specific HLA Antibody Production in Solid Organ Transplant Recipients.
OʼLeary JG; Samaniego M; Barrio MC; Potena L; Zeevi A; Djamali A; Cozzi E
Transplantation; 2016 Jan; 100(1):39-53. PubMed ID: 26680372
[TBL] [Abstract][Full Text] [Related]
7. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
[TBL] [Abstract][Full Text] [Related]
8. Humoral immunity and antibody-mediated rejection in solid organ transplantation.
Montgomery RA; Cozzi E; West LJ; Warren DS
Semin Immunol; 2011 Aug; 23(4):224-34. PubMed ID: 21958960
[TBL] [Abstract][Full Text] [Related]
9. CD38 Antibody Daratumumab for the Treatment of Chronic Active Antibody-mediated Kidney Allograft Rejection.
Doberer K; Kläger J; Gualdoni GA; Mayer KA; Eskandary F; Farkash EA; Agis H; Reiter T; Reindl-Schwaighofer R; Wahrmann M; Cohen G; Haslacher H; Bond G; Simonitsch-Klupp I; Halloran PF; Böhmig GA
Transplantation; 2021 Feb; 105(2):451-457. PubMed ID: 32235256
[TBL] [Abstract][Full Text] [Related]
10. Differences in pathologic features and graft outcomes in antibody-mediated rejection of renal allografts due to persistent/recurrent versus de novo donor-specific antibodies.
Haas M; Mirocha J; Reinsmoen NL; Vo AA; Choi J; Kahwaji JM; Peng A; Villicana R; Jordan SC
Kidney Int; 2017 Mar; 91(3):729-737. PubMed ID: 28104301
[TBL] [Abstract][Full Text] [Related]
11. Monitoring of Donor-specific Anti-HLA Antibodies and Management of Immunosuppression in Kidney Transplant Recipients: An Evidence-based Expert Paper.
Crespo M; Zárraga S; Alonso Á; Beneyto I; Díaz Corte C; Fernandez Rodriguez AM; Franco A; Hernández D; González-Roncero FM; Jiménez Martín C; Jimeno L; Lauzurica Valdemoros LR; Llorente S; Mazuecos A; Osuna A; Ramos JP; Rodríguez Benot A; Ruiz San Millán JC; Sánchez Fructuoso A; Torregrosa JV; Guirado L;
Transplantation; 2020 Aug; 104(8 Suppl 2):S1-S12. PubMed ID: 32658025
[No Abstract] [Full Text] [Related]
12. Nebulous humors: defining alloantibodies in the 21st century.
Warner P
Hum Immunol; 2009 Aug; 70(8):623-6. PubMed ID: 19374934
[No Abstract] [Full Text] [Related]
13. Reduction in proteinuria with bortezomib based therapy for antibody mediated rejection.
Lubetzky M; Auli MJ; Walker J; Leeser D; Kapur S; Hartono C; Dadhania D
Clin Transpl; 2010; ():437-40. PubMed ID: 21696061
[No Abstract] [Full Text] [Related]
14. Rescue therapy for acute antibody mediated rejection with a proteosome inhibitor after kidney transplantation.
Manitpisitkul W; Wilson NS; Philosophe B; Cooper M; Drachenberg C; Kukuruga D; Nogueira J; Haririan A
Clin Transpl; 2010; ():421-8. PubMed ID: 21698839
[No Abstract] [Full Text] [Related]
15. Posttransplant peripheral blood donor-specific interferon-γ enzyme-linked immune spot assay differentiates risk of subclinical rejection and de novo donor-specific alloantibodies in kidney transplant recipients.
Crespo E; Cravedi P; Martorell J; Luque S; Melilli E; Cruzado JM; Jarque M; Meneghini M; Manonelles A; Donadei C; Lloberas N; Gomà M; Grinyó JM; Heeger P; Bestard O
Kidney Int; 2017 Jul; 92(1):201-213. PubMed ID: 28274484
[TBL] [Abstract][Full Text] [Related]
16. Which human leukocyte antigen antibodies are really clinically relevant?
Opelz G; Claas FH
Hum Immunol; 2009 Aug; 70(8):561-2. PubMed ID: 19580832
[No Abstract] [Full Text] [Related]
17. Bortezomib use in chronic antibody-mediated allograft dysfunction: updates and additional cases.
Cooper JE; Wiseman AC; Chan L
Clin Transpl; 2010; ():415-20. PubMed ID: 21698838
[No Abstract] [Full Text] [Related]
18. Early Versus Late Acute Antibody-Mediated Rejection Among Renal Transplant Recipients in Terms of Response to Rituximab Therapy: A Single Center Experience.
Gheith O; Al-Otaibi T; Halim MA; Mahmoud T; Nair P; Monem MA; Al-Waheeb S; Hassan R; Nampoory N
Exp Clin Transplant; 2017 Feb; 15(Suppl 1):150-155. PubMed ID: 28260457
[TBL] [Abstract][Full Text] [Related]
19. Graft dysfunction in chronic antibody-mediated rejection correlates with B-cell-dependent indirect antidonor alloresponses and autocrine regulation of interferon-γ production by Th1 cells.
Shiu KY; McLaughlin L; Rebollo-Mesa I; Zhao J; Burton H; Douthwaite H; Wilkinson H; Semik V; Dodd PC; Brookes P; Lechler RI; Hernandez-Fuentes MP; Kemper C; Dorling A
Kidney Int; 2017 Feb; 91(2):477-492. PubMed ID: 27988211
[TBL] [Abstract][Full Text] [Related]
20. The Problem of Subclinical Antibody-mediated Rejection in Kidney Transplantation.
Filippone EJ; Farber JL
Transplantation; 2021 Jun; 105(6):1176-1187. PubMed ID: 33196628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
